Do Gluten Pills Work? What the Science Actually Says

Most over-the-counter gluten-digesting supplements fail to break down the specific gluten fragments that trigger immune reactions in people with celiac disease. A laboratory analysis of commercially available products found that their enzymes leave the key immunogenic pieces of gluten largely intact, despite marketing claims to the contrary. The reality is more complicated than “they work” or “they don’t,” because the type of enzyme matters enormously, and a few specific enzymes show genuine promise in clinical research. But the gap between what you can buy at a supplement store today and what the science suggests might actually help is wide.

What Is Actually Inside These Supplements

Walk down the digestive-health aisle and you will find dozens of products marketed as “gluten-digesting enzymes” or “glutenases.” Most contain some combination of proteases (enzymes that break apart proteins), along with amylases and lipases that handle starches and fats. The enzyme most frequently highlighted on labels is dipeptidyl peptidase IV, usually abbreviated as DPP-IV, which is a type of protease that clips amino acids from the ends of protein chains. Some products also include probiotics or herbal ingredients. A review of 14 commercially available glutenase products found that all contained proteases, eight contained DPP-IV, and eight failed to specify the name or origin of all their proteases.¹ That vagueness is a problem, because which protease a product contains determines whether it has any shot at working.

More specialized products contain prolyl endopeptidases, enzymes specifically designed to cut through the proline-rich sequences in gluten that resist normal digestion. Some supplements combine DPP-IV with starch-degrading enzymes and other proteases. Lab testing of commercial products found that supplements containing prolyl endopeptidase from Aspergillus niger (often labeled AN-PEP) showed the most rapid degradation of the immune-triggering gluten fragments, while products relying on DPP-IV plus starch-degrading enzymes produced more general protein breakdown but were not necessarily targeting the right pieces.²

Why Most Commercial Products Fall Short

Gluten is unusually resistant to digestion. Its proteins are loaded with proline and glutamine, two amino acids that create tightly folded structures most human digestive enzymes struggle to crack open. The fragments that survive digestion and trigger immune attacks in celiac disease are specific peptide sequences, most famously the “33-mer” from alpha-gliadin and the “26-mer” from gamma-gliadin. For a supplement to genuinely help, it needs to chop those specific sequences into pieces small enough that the immune system no longer recognizes them.

A direct test of commercially available enzyme supplements found that they don’t clear this bar. Researchers exposed these key immunogenic peptides to a range of supplement enzymes under conditions mimicking human digestion. Mass spectrometry showed the products contained plenty of enzyme activity in general, including amylases and various proteases. But the supplements left the nine immunogenic epitopes in the 26-mer and 33-mer gliadin fragments largely intact.³ In other words, the enzymes were doing something to gluten proteins, just not the thing that matters.

DPP-IV on its own is a particular disappointment. Because it is the most commonly marketed enzyme in gluten supplements, it deserves a close look. Researchers tested DPP-IV as a standalone agent against the 33-mer, the 26-mer, and another immune-stimulating gluten peptide. In each case, the enzyme produced minimal-to-no breakdown, generating only slightly truncated versions of the original fragments rather than neutralizing them.⁴ DPP-IV nibbles at the ends of these peptides but cannot cut through the middle where the immune-triggering sequences sit. Products that list DPP-IV as their primary or sole active enzyme are, by the available evidence, not going to meaningfully reduce immune-reactive gluten in your gut.

AN-PEP Shows Genuine Promise in the Lab and Stomach

Not all gluten-digesting enzymes are created equal, and one stands out in the research: prolyl endoprotease derived from the fungus Aspergillus niger, known as AN-PEP. Unlike DPP-IV, AN-PEP cuts through the interior of proline-rich peptide chains, which is exactly where the dangerous sequences live. Lab studies found AN-PEP works best at a pH of 4 to 5, stays stable in the highly acidic environment of the stomach (pH 2), and resists being broken down by pepsin, the stomach’s own protein-digesting enzyme. It degraded all tested immune-stimulating gluten peptides as well as intact gluten molecules, doing so roughly 60 times faster than another type of prolyl endopeptidase.⁵

That acid stability is critical. A gluten enzyme needs to survive the stomach and be active there, since the stomach is where food sits longest and where a supplement has the best window to work before gluten fragments move into the small intestine and encounter the immune system.⁶ Many proteases are either active at neutral pH and useless in stomach acid, or they get digested by pepsin before they can do their job. AN-PEP sidesteps both problems.

A randomized clinical trial moved AN-PEP from the lab into actual human stomachs. Healthy volunteers ate a meal containing gluten and took either a high dose of AN-PEP, a low dose, or a placebo. Researchers then measured gluten concentrations in the stomach and duodenum via intubation. Both doses of AN-PEP reduced gluten levels in the stomach by about 85 to 88 percent compared to placebo. In the duodenum, the reduction was about 48 to 56 percent.⁷ Those are impressive numbers for a supplement taken with a meal. But there is a catch.

The Celiac Disease Problem

Reducing gluten in the stomach is not the same as preventing immune damage in the small intestine, and this is where the story gets frustrating. A pilot study gave celiac disease patients toast containing about 7 grams of gluten per day (a substantial amount, roughly equivalent to two slices of regular bread) alongside AN-PEP or a placebo for two weeks. The primary endpoint was whether the enzyme prevented worsening of intestinal damage as measured by biopsy. The result was inconclusive: patients receiving placebo also did not deteriorate significantly during the two-week period, which meant the study could not distinguish between the AN-PEP group and the placebo group. Symptom scores and antibody levels did not differ between groups either.⁸

This is a common stumbling block in celiac research: the gluten dose and exposure period have to be calibrated precisely. Too little gluten or too short a window, and even the placebo group will look fine, leaving the study unable to detect whether the enzyme helped. The AN-PEP pilot is not evidence that the enzyme failed, but it is also far from evidence that it protects celiac patients from real-world gluten exposure. No enzyme supplement has been proven in a rigorous clinical trial to prevent intestinal damage from gluten in people with celiac disease. That is the uncomfortable reality, and any supplement marketed with that implication is getting ahead of the science.

A Brighter Picture for Non-Celiac Gluten Sensitivity

The evidence looks somewhat more encouraging for people who experience symptoms after eating gluten but do not have celiac disease, a condition known as non-celiac gluten sensitivity (NCGS). A randomized, placebo-controlled crossover study tested an enzyme mixture in NCGS patients who underwent a gluten challenge. Participants who took the enzyme mixture showed significantly lower symptom scores after gluten exposure compared to when they took placebo. The improvements were particularly clear for feelings of incomplete evacuation and headaches.⁹

The distinction matters. In celiac disease, even tiny amounts of gluten can provoke a destructive autoimmune attack on the intestinal lining, so an enzyme that reduces gluten by 85 percent might still leave enough to cause damage. In NCGS, the mechanism is different and the threshold for triggering symptoms appears to be higher. A partial reduction in gluten load could be enough to keep symptoms at bay for some people. That said, NCGS itself remains a somewhat contested diagnosis, and placebo effects in symptom-based conditions can be large. This was a single study, and more evidence is needed before drawing firm conclusions.

The Regulatory Gap

All of the gluten enzyme products currently on the market are classified as dietary supplements, not drugs. This distinction has major practical consequences. Dietary supplements are exempt from many FDA labeling standards that apply to pharmaceuticals.¹ Manufacturers do not have to prove their product works before selling it. They do not have to demonstrate that the enzymes survive stomach acid, that they are active at the relevant pH, or that they break down the specific gluten fragments that cause harm. They cannot legally claim to treat celiac disease, but they can use language like “supports gluten digestion” or “helps with occasional gluten exposure,” which many consumers reasonably interpret as meaning the product will protect them.

The labeling problems go beyond efficacy claims. Among the 14 glutenase products analyzed in the review mentioned earlier, one declared wheat as an allergen, meaning a product marketed to people who react to gluten actually contained a gluten source. Two contained herbal products whose type was not specified. Thirteen of the fourteen claimed to degrade immunogenic gluten fragments, a claim that lab evidence does not support for most of them. For a product category aimed at a vulnerable population, this level of regulatory oversight is thin.

Pharmaceutical-Grade Enzymes in Development

The limitations of over-the-counter supplements have pushed researchers toward developing pharmaceutical-grade enzyme therapies held to drug-approval standards. The most advanced of these is latiglutenase, a combination of two engineered enzymes that target gluten’s immunogenic sequences. Its clinical history illustrates how hard this problem is to crack.

In a gluten-challenge study, latiglutenase showed meaningful mucosal protection. Celiac patients on a gluten-free diet were exposed to deliberate gluten and given either latiglutenase or placebo. In the placebo group, intestinal damage worsened substantially: the ratio of villous height to crypt depth (a standard biopsy measure of gut health) dropped and immune cells flooded the intestinal lining. In the latiglutenase group, worsening was reduced by roughly 88 percent for villous architecture and 60 percent for immune cell infiltration compared to placebo.¹⁰

But a larger “real-world” trial, where patients simply continued their normal gluten-free diets and took latiglutenase or placebo, found no difference between the two groups in villous atrophy, immune cell counts, or celiac blood markers.¹¹ Researchers attributed this partly to a Hawthorne effect: knowing they were in a clinical trial, patients appeared to become more careful about their diets, reducing the already-small amount of accidental gluten that the enzyme was supposed to handle. This is an underappreciated problem for the entire field. If a therapy is designed to mop up trace gluten contamination, and participants in a trial naturally clean up their diets, the trial loses its ability to detect a benefit.

A more encouraging signal came from a subgroup analysis. Among patients who remained seropositive (still showing celiac antibodies in their blood despite following a gluten-free diet for at least a year, suggesting ongoing inadvertent gluten exposure), latiglutenase at the highest dose reduced the severity of abdominal pain by about 58 percent and bloating by about 44 percent relative to placebo.¹² Seropositive patients are arguably the ones who need help most, since their blood tests suggest the gluten-free diet alone is not controlling their disease. Whether latiglutenase will eventually reach the market remains to be seen, but the seropositive findings have shaped how researchers think about which patients these therapies might benefit.

Beyond Enzymes: Tight Junction Regulators

Not every experimental approach to gluten-related intestinal damage involves breaking down gluten itself. A completely different strategy targets the gut’s barrier function. When gluten fragments reach the intestinal lining in celiac disease, they trigger the release of a protein called zonulin, which loosens the tight junctions between intestinal cells. This increased permeability allows gluten peptides to slip past the barrier and provoke the full immune response. Larazotide acetate, a synthetic peptide in phase III clinical trials, works as a zonulin antagonist, essentially telling those junctions to stay closed even in the presence of gluten.¹³

Rather than destroying gluten before it reaches the intestine, larazotide acetate tries to keep gluten fragments on the outside where they can pass through harmlessly. Early-phase trials showed it reduced gluten-induced increases in intestinal permeability and gastrointestinal symptom severity in celiac patients exposed to a gluten challenge.¹⁴ It is not an enzyme supplement and would not be sold alongside digestive aids; if approved, it would be a prescription drug. But its existence underscores a point about the enzyme supplements lining store shelves: the problem of protecting a celiac gut from gluten is hard enough that major pharmaceutical companies are exploring fundamentally different biological mechanisms to solve it. The idea that a $20 bottle of DPP-IV capsules can do the job strains credibility.

Tracking Whether Gluten Slips Through

One development that could eventually clarify whether any enzyme product works in real life is a test that measures gluten immunogenic peptides in stool, sometimes abbreviated as f-GIP. This noninvasive method detects fragments of gluten that survived digestion and passed through the gut, and has been proposed as a way to check how well someone is actually adhering to a gluten-free diet.¹⁵ In principle, you could use this test to see whether taking an enzyme supplement actually reduces the amount of intact immunogenic gluten getting through. Some research groups are already heading in this direction, and if validated, f-GIP testing could provide the kind of individual, real-world feedback that clinical trials have struggled to deliver.

For now, though, the practical picture is lopsided. People with celiac disease should not treat any currently available supplement as a safety net that allows them to eat gluten. People with NCGS have at least some early clinical evidence that certain enzyme mixtures may reduce symptoms, though the evidence base is slim. And everyone shopping for these products should be aware that most of the enzymes being sold have not been shown to break down the gluten fragments that matter, regardless of what the packaging implies.

Which Enzymes Are Worth Watching

If you are determined to try an enzyme supplement, the research draws a clear line between enzymes that can and cannot handle gluten’s unique structure. Products containing AN-PEP (prolyl endopeptidase from Aspergillus niger) have the most laboratory and early clinical support. AN-PEP is active in stomach acid, resists pepsin, and targets the interior of the proline-rich sequences that other enzymes skip over.⁵ Some commercial supplements now include AN-PEP, and products containing it generally outperform those relying on DPP-IV or generic protease blends in lab comparisons.¹⁶

That said, outperforming a product that barely works is a low bar. Even AN-PEP’s strongest clinical result, the roughly 85 percent reduction in stomach gluten, leaves a meaningful residual. For someone with celiac disease whose immune system can react to milligrams of gluten, a supplement that eliminates most but not all of the gluten in a meal is not a reliable shield. It might have a role as one layer of protection on top of a gluten-free diet, helping to neutralize trace contamination from shared kitchens or restaurant meals. But “helpful insurance against cross-contamination” and “eat whatever you want” are very different promises, and most supplement marketing leans heavily toward the latter.